Global Exocrine Pancreatic Insufficiency Market to Reach $7.9 Billion by 2030
The global market for Exocrine Pancreatic Insufficiency estimated at US$5 Billion in the year 2022, is projected to reach a revised size of US$7.9 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2022-2030. Therapeutics, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$4.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Diagnostics segment is readjusted to a revised 6.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 5.4% CAGR
The Exocrine Pancreatic Insufficiency market in the U.S. is estimated at US$1.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 5.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.Select Competitors (Total 46 Featured) -
- AbbVie, Inc.
- Allergan PLC
- Anthera Pharmaceuticals, Inc.
- AzurRx BioPharma, Inc.
- Cilian AG
- Digestive Care, Inc.
- Janssen Pharmaceuticals, Inc.
- Nordmark Arzneimittel GmbH & Co. KG
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Allergan PLC
- Anthera Pharmaceuticals, Inc.
- AzurRx BioPharma, Inc.
- Cilian AG
- Digestive Care, Inc.
- Janssen Pharmaceuticals, Inc.
- Nordmark Arzneimittel GmbH & Co. KG
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 196 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 5 Billion |
Forecasted Market Value ( USD | $ 7.9 Billion |
Compound Annual Growth Rate | 5.9% |
Regions Covered | Global |